Moderna completes filing process for full approval of COVID-19 vaccine

Aug 25 (Reuters) - Moderna Inc has completed the real-time review process for its application to the U.S. Food and Drug Administration (FDA) seeking full approval for its COVID-19 vaccine in people aged 18 years and above, the company said on Wednesday. 

  As part of the completed submission, Moderna has requested a priority review designation for its vaccine. (Reporting by Mrinalika Roy in Bengaluru; Editing by Saumyadeb Chakrabarty) 

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting